September 17, 2016
This article originally appeared in MD Magazine.
With new antiviral drugs available to prevent HIV infection–and more in the pipeline–the US Centers for Disease Control and Prevention (CDC) and other government entities and non-profit organizations are launching pilot projects to get at-risk people to take these pre-exposure prophylactics.
“We’re scaling up,” said the CDC’s Karen Hoover, MD, MPH.
“Most people using PrEP are white men, of course, and it is black and Hispanic men who are at high risk–we havent been as successful with them,” she said.
Working with Gilead ,the maker of tenofovir ( Truvada), and various state and local government agencies and non-profit organizations, the CDC is assisting in setting up two large programs, one called THRIVE and another called PRIDE.